<DOC>
	<DOCNO>NCT02310412</DOCNO>
	<brief_summary>The objective study test hypothesis INTERCEPT platelet component store 7 day retain sufficient viability therapeutic efficacy . The post-infusion recovery lifespan 7-day old INTERCEPT platelet component store 35 % plasma 65 % InterSol store 100 % plasma , measure comparison `` fresh '' radiolabeled platelet accord FDA guidance platelet test ( FDA 1999 ) .</brief_summary>
	<brief_title>A Controlled , In Vivo , Pilot Study Assess Recovery Survival Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components 35 % Plasma 65 % InterSol 7-Day Stored Apheresis Platelet Components 100 % Plasma</brief_title>
	<detailed_description>The two stage pilot study consist follow : single double-dose platelet apheresis collection , pathogen inactivation INTERCEPT treatment , storage 7 day , collection fresh platelet , radiolabeling , infusion fresh store INTERCEPT treat radiolabeled autologous platelet , collection blood sample assessment platelet recovery survival ( lifespan ) . In Stage A , apheresis platelet collect use Amicus separator store 7 day 35 % Plasma 65 % InterSol . In Stage B , apheresis platelet collect use Trima separator store 7 day 100 % plasma . Procedures stag follow : On Day 0 , healthy volunteer subject apheresis platelet collect . INTERCEPT treatment begin either day donation ( Day 0 ) end day follow donation ( Day 1 ) . Platelets store 7 day collection ( Day 7 ) . Aliquots vitro platelet function take Day 0/1 INTERCEPT treatment Day 7 . An aliquot bacterial detection take Day 5 . On Day 7 , healthy volunteer return laboratory , 43 mL blood drawn syringe contain 9 mL Anticoagulant Citrate Dextrose Solution , Formula A ( ACD-A ) . Fresh platelet prepared sample . An aliquot ( 10-20 mL ) store ( INTERCEPT treat ) platelet aseptically remove subject 's test container . Previously store ( Test ) fresh ( Control ) platelet radiolabeled accord randomization assignment either 51Cr ( ≤20 μCi ) sodium radiochromate ( Na251CrO4 ) , 111In ( ≤15 μCi ) indium oxine , follow label wash procedure outline Biomedical Excellence Safer Transfusion ( BEST ) Collaborative . The isotope label determine random number table equal number fresh store ( INTERCEPT treat ) platelet label isotope . Aliquots fresh store platelet radiolabeled tubes standard technique . After radiolabeling , autologous fresh store platelet simultaneously infuse subject ( approximately 10-30 mL ) . Negative bacteria detection test negative pregnancy test female childbearing potential require infusion . Blood sample radioactivity measurement draw 0 ( pre-infusion ) , 0.5 , 1 , 2 hour post-infusion , 6 sample draw 1 , 2 , 3 , 4 ( 6 ) , 7±1 , 10±1 day post-infusion . In addition , logistically feasible , additional sample obtain 5 day post-infusion ( optional ) . Radioactivity measurement Samples obtain radiolabeled fresh store platelet infusion use radioactive standard . By measure volume infuse , total dose radioactivity infuse calculate . In vitro elution label transfuse platelet determine two elution assessment method , well vivo elution radioactivity serial blood sample obtain post-infusion labeled platelet . The standard well subject 's whole-blood sample correct elution also residual activity cellular fraction Day 8 . The first four data point post-infusion use calculate vivo recovery survival radioactive correction make . The radioactivity sample determine use gamma counter . A multiple-hit model , computerized program `` COST , '' use estimate recovery survival radioactively label platelet .</detailed_description>
	<criteria>Ageminimum 18 year , either gender Normal health status ( determine Investigator review medical history blood donor physical exam ) Meet FDA AABB guideline autologous apheresis platelet donation Complete blood count ( CBC ) serum chemistry value within normal limit Predonation platelet count 150×109 platelets/L Negative blood donor screen test panel HIV , HBV , HCV , HTLV , syphilis , WNV Male female subject childbearing potential must agree use medically acceptable method contraception throughout study . A barrier method contraception must include , regardless method . Signed date informed consent form Clinically significant acute chronic disease ( determined Investigator ) Pregnant nursing female Male female subject childbearing potential use effective contraception Disease state condition preclude blood donation apheresis platelet donation per AABB reference standard Treatment aspirin aspirin contain medication within 7 day apheresis treatment nonsteroidal antiinflammatory drug ( NSAID ) , antiplatelet agent drug affect platelet viability within 3 day apheresis ( e.g . ibuprofen NSAIDs ) Smokers use &gt; 10 cigarettes/day last 3 month Splenectomized subject Prior exposure amotosalen History know hypersensitivity indium chromium Participation another clinical study currently within past 28 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>INTERCEPT</keyword>
	<keyword>platelet</keyword>
	<keyword>pathogen inactivation</keyword>
	<keyword>platelet component store</keyword>
	<keyword>therapeutic efficacy</keyword>
</DOC>